FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Equine Vet J / Assessing omeprazole and flunixin meglumine co-administratio...
Equine veterinary journal2025; doi: 10.1111/evj.14477

Assessing omeprazole and flunixin meglumine co-administration in treating equine gastric ulcer syndrome in Mongolian horses.

Abstract: Flunixin meglumine (FM) is commonly used in painful conditions in horses; however, it may contribute to equine gastric ulcer syndrome (EGUS). Some veterinarians combine omeprazole (OME) and FM to reduce EGUS risk. However, the efficacy and safety of this combination in Mongolian horses with chronic lameness remain unknown. Objective: To investigate the changes in lameness and EGUS scores in Mongolian horses through the comparison of three treatment strategies: FM, FM + OME and placebo treated control (CON) and to assess the effects of these treatments on gastric fluid pH, serum total protein, albumin and oxidative stress markers (MPO, SOD, CAT). Methods: In vivo experiments. Methods: Eighteen Mongolian horses with initial American Association of Equine Practitioners lameness scores ≥3 of 5 were selected and equally divided into the placebo (CON), FM (1.1 mg/kg IV q. 24 h) and FM + OME (4 mg/kg PO q. 24 h) treatment groups in a randomised block design. During 15 days of treatment, weekly gastroscopy and physiological and biochemical tests were performed. Stomach tissues were harvested from two horses from each group for histopathological examination with haematoxylin and eosin, Masson's trichrome and periodic acid-Schiff (PAS) staining. Results: FM (median 1.0, interquartile range 0.0-1.0; p < 0.001) and FM + OME (1.0, 1.0-1.0; p < 0.001) significantly decreased lameness scores compared with CON (3.0, 3.0-4.0). Compared with CON (EGGD: 0.0, 0.0-1.0, p < 0.001; PG1: mean 231.9 ± standard deviation 25.2 ng/mL, p < 0.001) or FM + OME (EGGD: 0.8, 1.0-1.3, p = 0.003; PG1: 207.08 ± 34.85 ng/mL, p < 0.001), FM significantly increased equine gastric glandular disease (EGGD) grade (3.0, 2.0-3.3) and pepsinogen 1 (PG1) content (372.2 ± 33.2 ng/mL, p < 0.001). Compared with CON (total protein: 70.1 ± 2.9 g/L; albumin: 37.0 ± 3.0 g/L; Gastrin-17: 482.5 ± 48.1 pg/mL), FM significantly reduced total protein (62.8 ± 2.9 g/L, p = 0.003), albumin (31.5 ± 2.3 g/L, p = 0.01) and Gastrin-17 (GT-17) content (284.6 ± 57.2 pg/mL, p < 0.001). Compared with FM (EGGD: 3.0, 2.0-3.3; pH: 2.4 ± 0.3), FM + OME significantly decreased the EGGD grade (0.8, 1.0-1.3; p = 0.003) and significantly increased gastric fluid pH (7.4 ± 0.2; p < 0.001). FM + OME (207.1 ± 34.9 ng/mL) significantly decreased PG1 content compared with FM (372.24 ± 33.25 ng/mL; p < 0.001). Histopathology revealed that 15 days of FM treatment led to gastric lesions in horses, which were mitigated by combining with OME. Conclusions: Individual differences among horses were large, but the sample size was small and sampling was infrequent. Conclusions: Compared with FM alone, use of FM + OME did not impact the reduction in lameness scores with therapy, but reduced the occurrence of EGGD in Mongolian horses. When used to manage chronic lameness, FM + OME might protect against FM-induced EGGD by increasing the gastric pH and decreasing serum PG1 content.
© 2025 EVJ Ltd.
Get Full Text
Publication Date: 2025-02-18 PubMed ID: 39967295DOI: 10.1111/evj.14477Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This study investigates the efficacy of co-administering flunixin meglumine (FM) and omeprazole (OME) in treating equine gastric ulcer syndrome (EGUS) and lameness in Mongolian horses. The authors found that the combined use of FM and OME demonstrated protective effects against FM-induced EGUS in these horses, with the additional benefit of reducing lameness, which FM treatment alone also achieved.

Study Design and Methodology

  • The study involved in vivo experiments with eighteen Mongolian horses that presented with signs of lameness. These horses were randomly divided into three groups – placebo (CON), FM alone, and FM combined with OME.
  • Both FM and the FM + OME regimen were administered for a period of 15 days. During this period, weekly gastroscopy and physiological and biochemical analyses were performed to monitor changes brought about by the treatment.
  • Furthermore, stomach tissues were harvested from two horses in each group for histopathological examination using various staining techniques.

Key Results

  • Both FM alone and the FM + OME combination significantly reduced lameness scores compared to the control group.
  • Treatment with FM alone was found to increase gastric glandular disease (EGGD) and pepsinogen 1 (PG1) content, markers of gastric ulcers in horses. However, these were significantly reduced when OME was added to the FM treatment.
  • FM treatment also led to a significant reduction in serum total protein, albumin, and Gastrin-17 content. This phenomenon was not observed in the FM + OME group, which could indicate potential mitigation of FM’s side effects when OME is co-administered.
  • Gastric fluid pH observed to be lower in the FM group increased significantly when OME was added, indicative of a healthier gastric environment.
  • GAstroscopic pathology revealed that gastric lesions induced by FM treatment were mitigated when OME was added, confirming the protective effect of the drug combination.

Conclusions

  • The study concludes that although both FM alone and FM + OME treatment reduced lameness in the horses, the combined therapy was superior in terms of protecting against FM-induced EGGD.
  • This advantage was achieved by increasing the gastric pH and decreasing serum PG1 content, thereby creating a more favourable environment in the horses’ stomach.
  • However, the authors also note that the sample size for this study was small and the horses exhibited significant individual differences, which may affect the generalizability of the findings.

Cite This Article

APA
Guo W, Li Z, Mao W, Liu X, Yang Y, Yu J, Yang H, Gao R. (2025). Assessing omeprazole and flunixin meglumine co-administration in treating equine gastric ulcer syndrome in Mongolian horses. Equine Vet J. https://doi.org/10.1111/evj.14477

Publication

Equine veterinary journal
ISSN: 2042-3306
NlmUniqueID: 0173320
Country: United States
Language: English

Researcher Affiliations

Guo, Wenrui
  • Animal Embryo and Developmental Engineering Key Laboratory of Higher Education, Institutions of Inner Mongolia Autonomous Region, Hohhot, China.
  • College of Veterinary Medicine, Inner Mongolia Agricultural University, Hohhot, China.
Li, Zhengyi
  • Animal Embryo and Developmental Engineering Key Laboratory of Higher Education, Institutions of Inner Mongolia Autonomous Region, Hohhot, China.
  • College of Veterinary Medicine, Inner Mongolia Agricultural University, Hohhot, China.
Mao, Wei
  • Animal Embryo and Developmental Engineering Key Laboratory of Higher Education, Institutions of Inner Mongolia Autonomous Region, Hohhot, China.
  • College of Veterinary Medicine, Inner Mongolia Agricultural University, Hohhot, China.
Liu, Xinyu
  • Animal Embryo and Developmental Engineering Key Laboratory of Higher Education, Institutions of Inner Mongolia Autonomous Region, Hohhot, China.
  • College of Veterinary Medicine, Inner Mongolia Agricultural University, Hohhot, China.
Yang, Ying
  • Animal Embryo and Developmental Engineering Key Laboratory of Higher Education, Institutions of Inner Mongolia Autonomous Region, Hohhot, China.
  • College of Veterinary Medicine, Inner Mongolia Agricultural University, Hohhot, China.
Yu, Jiahui
  • Animal Embryo and Developmental Engineering Key Laboratory of Higher Education, Institutions of Inner Mongolia Autonomous Region, Hohhot, China.
  • College of Veterinary Medicine, Inner Mongolia Agricultural University, Hohhot, China.
Yang, Huidi
  • Basic Medical School, Inner Mongolia Medical University, Hohhot, China.
Gao, Ruifeng
  • Animal Embryo and Developmental Engineering Key Laboratory of Higher Education, Institutions of Inner Mongolia Autonomous Region, Hohhot, China.
  • College of Veterinary Medicine, Inner Mongolia Agricultural University, Hohhot, China.

Grant Funding

  • YLXKZX-NND-012 / Research Special Project of First-Class Discipline by the Education Department of Inner Mongolia Autonomous Region
  • 2023MS03035 / Natural Science Foundation of Inner Mongolia Autonomous Region
  • 2023LHMS03015 / Natural Science Foundation of Inner Mongolia Autonomous Region
  • NJYT24056 / Program for Young Talents of Science and Technology in Universities of Inner Mongolia Autonomous Region
  • 32160247 / National Natural Science Foundation of China
  • YKD2023ZD007 / Key Projects of Inner Mongolia Medical University

References

This article includes 84 references
  1. Urayama S, Tanaka A, Kusano K, Sato H, Muranaka M, Mita H. Oral administration of meloxicam and flunixin meglumine have similar analgesic effects after lipopolysaccharide‐induced inflammatory response in thoroughbred horses.. J Equine Vet Sci 2023;121:104205.
  2. Bishop RC, McCoy AM, Kemper AM, Stewart RM, Wilkins PA. Short‐term administration of flunixin meglumine or firocoxib does not alter viscoelastic coagulation profiles in healthy horses.. J Am Vet Med Assoc 2022;260(15):1963–1966.
  3. Lemonnier LC, Thorin C, Meurice A, Dubus A, Touzot‐Jourde G, Couroucé A. Comparison of flunixin meglumine, meloxicam and ketoprofen on mild visceral post‐operative pain in horses.. Animals 2022;12(4):526.
  4. Gobbi FP, Di Filippo PA, de Macêdo ML, Lemos GB, Martins CB, Albernaz AP. Effects of flunixin meglumine, firocoxib, and meloxicam in equines after castration.. J Equine Vet Sci 2020;94:103229.
  5. Vernilimer CD, Hennessy PW. Clinical studies on flunixin meglumine in the treatment of equine colic.. J Equine Med Surg 1977;1:111–116.
  6. Houndshell JW, Hennesss SW. A new NSAID analgesic for horses.. J Equine Med Surg 1977;1:57–63.
  7. Bottoms GD, Fessler JF, Roesel OF, Moore AD, Fraunfelder HC. Endotoxin induced hemodynamic changes in ponies: effects of flunixin meglumine.. Am J Vet Res 1981;42:1514–1518.
  8. Fessler JF, Bottoms FD, Roesel OF, Moore AD, Fraunfelder HC, Boon CD. Endotoxin induced changes in hemograms, plasma enzymes and blood chemical values in anesthetized ponies: effects of flunixin meglumine.. Am J Vet Res 1982;43:140–144.
  9. Moore JN, Garner HE, Shapland HE, Hatfield DG. Prevention of endotoxin‐induced arterial hypoxaemia and lactic acidosis with flunixin meglumine in conscious ponies.. Equine Vet J 1981;13:95–98.
  10. Dunkle NJ, Bottoms GD, Fessler JF, Knox K, Roesel OF. Effects of flunixin meglumine on blood pressure and fluid compartment volume changes in ponies given endotoxin.. Am J Vet Res 1985;46:1540–1544.
  11. Palmer JE. Gastrointestinal diseases of foals.. Vet Clin North Am Equine Pract 1985;1:151–168.
  12. Willard MD. Newer concepts in the treatment of secretory diarrhea.. J Am Vet Med Assoc 1985;186:86–88.
  13. Knych HK. Nonsteroidal anti‐inflammatory drug use in horses.. Vet Clin North Am Equine Pract 2017;33:1–15.
  14. Davis JL. Nonsteroidal anti‐inflammatory drug associated right dorsal colitis in the horse.. Equine Vet Educ 2017;29:104–113.
  15. Cook VL, Blikslager AT. The use of nonsteroidal anti‐inflammatory drugs in critically ill horses.. J Vet Emerg Crit Care 2015;25:76–88.
  16. Stefanyk O, Slivinska L. Pathomorphological study on gastric ulceration in horses.. Scientific messenger of LNU of veterinary medicine and biotechnologies. Ser Vet Sci 2019;21(96):192–197.
  17. Collins L, Tyler D. Experimentally induced phenylbutazone toxicosis in ponies: description of the syndrome and its prevention with synthetic prostaglandin E2.. Am J Vet Res 1985;46:1605–1615.
  18. American Association of Equine Practitioners (AAEP). Lameness scale. Definition and classification of lameness. Guide for veterinary service and judging of equestrian events.. 4th ed. Lexington, KY: American Association of Equine Practitioners; 1991. p. 19.
  19. Andrews F, Bernard W, Byars D, Cohen N, Divers T, MacAllister C. Recommendations for the diagnosis and treatment of equine gastric ulcer syndrome (EGUS).. Equine Vet Educ 1999;11(5):262–272.
  20. Sykes BW, Hewetson M, Hepburn RJ, Luthersson N, Tamzali Y. European College of Equine Internal Medicine Consensus Statement—equine gastric ulcer syndrome in adult horses.. J Vet Intern Med 2015;29:1288–1299.
  21. Ricord M, Andrews FM, Yñiguez FJM, Keowen M, Garza F Jr, Paul L. Impact of concurrent treatment with omeprazole on phenylbutazone‐induced equine gastric ulcer syndrome (EGUS).. Equine Vet J 2021;53(2):356–363.
  22. Mackay RJ, French TW, Nguyen HT, Mayhew IG. Effects of large doses of phenylbutazone administration to horses.. Am J Vet Res 1983;44:774–780.
  23. Snow DH, Douglas TA, Thompson H, Parkins JJ, Holmes PH. Phenylbutazone toxicosis in equidae: a biochemical and pathophysiological study.. Am J Vet Res 1981;42:1754–1759.
  24. MacAllister CG, Morgan SJ, Borne AT, Pollet RA. Comparison of adverse effects of phenylbutazone, flunixin meglumine, and ketoprofen in horses.. J Am Vet Med Assoc 1993;202:71–77.
  25. Raidal SL, Andrews FM, Nielsen SG, Trope G. Pharmacokinetic and pharmacodynamic effects of two omeprazole formulations on stomach pH and gastric ulcer scores.. Equine Vet J 2017;49(6):802–809.
  26. Van den Boom R. Equine gastric ulcer syndrome in adult horses.. Vet J 2022;283:105830.
  27. Lester GD, Smith RL, Robertson ID. Effects of treatment with omeprazole or ranitidine on gastric squamous ulceration in racing thoroughbreds.. J Am Vet Med Assoc 2005;227:1636–1639.
  28. Sykes BW. Courses for horses: rethinking the use of proton pump inhibitors in the treatment of equine gastric ulcer syndrome.. Equine Vet Educ 2019;31(8):441–446.
  29. Shan R, Steel CM, Sykes B. The impact of two recommended withholding periods for omeprazole and the use of a nutraceutical supplement on recurrence of equine gastric ulcer syndrome in thoroughbred racehorses.. Animals 2023;13(11):1823.
  30. Gwee KA, Goh V, Lima G, Setia S. Coprescribing proton‐pump inhibitors with nonsteroidal anti‐inflammatory drugs: risks versus benefits.. J Pain Res 2018;11:361–374.
  31. Bishop RC, Wilkins PA, Kemper AM, Stewart RM, McCoy AM. Effect of firocoxib and flunixin meglumine on large colon mural thickness of healthy horses.. J Equine Vet Sci 2023;126:104562.
  32. Pearson EG, Smith BB, McKim JM. Fecal blood determinations and interpretation.. Proc Am Assoc Equine Pract 1987;33:77–81.
  33. Sykes BW, Sykes KM, Hallowell GD. A comparison of two doses of omeprazole in the treatment of equine gastric ulcer syndrome: a masked, randomised, clinical trial.. Equine Vet J 2014;46:416–421.
  34. Wallace JL, Syer S, Denou E, de Palma G, Vong L, McKnight W. Proton pump inhibitors exacerbate NSAID‐induced small intestinal injury by inducing dysbiosis.. Gastroenterology 2011;141:1314–1322. e5.
  35. Whitfield‐Cargile CM, Chamoun‐Emanuelli AM, Cohen ND, Richardson LM, Ajami NJ, Dockery HJ. Differential effects of selective and non‐selective cyclooxygenase inhibitors on fecal microbiota in adult horses.. PLoS One 2018;13:e0202527.
  36. Jamieson J, Kutryk M. Studies on the effect of phenylbutazone and salicylate on the rates of synthesis of albumin and acute‐phase α1‐acid glycoprotein by rat liver slices.. Biochem Med 1980;23:293–301.
  37. Meschter CL, Gilbert M, Krook L, Maylin G, Corradino R. The effects of phenylbutazone on the intestinal mucosa of the horse: a morphological, ultrastructural and biochemical study.. Equine Vet J 1990;22(4):255–263.
  38. Cohen ND, Carter GK, Mealey RH, Taylor TS. The recognition and medical management of right dorsal colitis in horses.. Vet Med 1995;9:272–276.
  39. MacAllister CG, Sangiah S. Effect of ranitidine on healing of experimentally induced gastric ulcers in ponies.. Am J Vet Res 1993;54(7):1103–1107.
  40. Rainsford K, Willis C. Relationship of gastric mucosal damage induced in pigs by anti‐inflammatory drugs to their effects on prostaglandin production.. Dig Dis Sci 1982;2:624–635.
  41. Mahmud T, Rafi SS, Scott DL, Wrigglesworth JM, Bjarnason I. Nonsteroidal antiinflammatory drugs and uncoupling of mitochondrial oxidative phosphorylation.. Arthritis Rheum 1996;39:1998–2003.
  42. Goddard PJ, Hills BA, Lichtenberger LM. Does aspirin damage canine gastric mucosa by reducing its surface hydrophobicity?. Am J Physiol Gastrointest Liver Phys Ther 1987;252:G421–G430.
  43. Goddard PJ, Kao Y‐CJ, Lichtenberger LM. Luminal surface hydrophobicity of canine gastric mucosa is dependent on a surface mucous gel.. Gastroenterology 1990;98:361–370.
  44. Ruiz‐Hurtado PA, Garduño‐Siciliano L, Dominguez‐Verano P, Martinez‐Galero E, Canales‐Martinez MM, Rodriguez‐Monroy MA. Evaluation of the gastroprotective effects of Chihuahua propolis on indomethacin‐induced gastric ulcers in mouse.. Biomed Pharmacother 2021;137:111345.
  45. Tan B, Chiranthanut N, Chansakaow S, Sireeratawong S, Khonsung P, Nimlamool W. Gastroprotective effects of Pikad Tri‐phol‐sa‐mut‐than herbal remedy on multiple gastric ulcer models in rats.. Heliyon 2023;9(8):e19297.
  46. Kamar SA, Bayoumi AH, Rady HY. Spirulina supplements: an approach moderating aspirin pers귭 histological and ultra‐structural alterations in albino rats gastric mucosa.. Ultrastruct Pathol 2022;46(2):204–216.
  47. Sánchez S, Martín MJ, Ortiz P, Motilva V, Alarcón de la Lastra C. Effects of dipyrone on inflammatory infiltration and oxidative metabolism in gastric mucosa: comparison with acetaminophen and diclofenac.. Dig Dis Sci 2002;47(6):1389–1398.
  48. Wallace JL, McKnight W, Reuter BK, Vergnolle N. NSAID‐induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2.. Gastroenterology 2000;119:706–714.
  49. Takeuchi K, Ueshima K, Hironaka Y, Fujioka Y, Matsumoto J, Okabe S. Oxygen free radicals and lipid peroxidation in the pathogenesis of gastric mucosal lesions induced by indomethacin in rats. Relation to gastric hypermotility.. Digestion 1991;49(3):175–184.
  50. Miura T, Muraoka S, Fujimoto Y. Lipid peroxidation induced by indomethacin with horseradish peroxidase and hydrogen peroxide: involvement of indomethacin radicals.. Biochem Pharmacol 2002;63(11):2069–2074.
  51. Coskun T, Yeğen BC, Alican I, Peker O, Kurtel H. Cold restraint stress‐induced gastric mucosal dysfunction. Role of nitric oxide.. Dig Dis Sci 1996;41(5):956–963.
  52. Takeuchi K, Yasuhiro T, Asada Y, Sugawa Y. Role of nitric oxide in pathogenesis of aspirin‐induced gastric mucosal damage in rats.. Digestion 1998;59(4):298–307.
  53. Oyagi A, Ogawa K, Kakino M, Hara H. Protective effects of a gastrointestinal agent containing Korean red ginseng on gastric ulcer models in mice.. BMC Complement Altern Med 2010;10:45.
  54. Devi RS, Narayan S, Vani G, Shyamala Devi CS. Gastroprotective effect of Terminalia arjuna bark on diclofenac sodium induced gastric ulcer.. Chem Biol Interact 2007;167:71–83.
  55. Halliwell B. Free radicals, antioxidants, and human disease: curiosity, cause, or consequence?. Lancet 1994;344:721–724.
  56. Mahadik SP, Scheffer RE. Oxidative injury and potential use of antioxidants in schizophrenia.. Prostaglandins Leukot Essent Fatty Acids 1996;55(1–2):45–54.
  57. Odabasoglu F, Halici Z, Cakir A, Halici M, Aygun H, Suleyman H. Beneficial effects of vegetable oils (corn, olive and sunflower oils) and alpha‐tocopherol on anti‐inflammatory and gastrointestinal profiles of indomethacin in rats.. Eur J Pharmacol 2008;591(1–3):300–306.
  58. Contreras‐Aguilar MD, Rubio CP, González‐Arostegui LG, Martín‐Cuervo M, Cerón JJ, Ayala I. Changes in oxidative status biomarkers in saliva and serum in the equine gastric ulcer syndrome and colic of intestinal aetiology: a pilot study.. Animals 2022;12(5):667.
  59. Biswas SK. Does the interdependence between oxidative stress and inflammation explain the antioxidant paradox?. Oxid Med Cell Longev 2016;2016:5698931.
  60. Kishimoto T. Interleukin‐6: from basic science to medicine—40 years in immunology.. Annu Rev Immunol 2005;23:1–21.
  61. Ahmed SM, Luo L, Namani A, Wang XJ, Tang X. Nrf2 signaling pathway: pivotal roles in inflammation.. Biochim Biophys Acta Mol Basis Dis 2017;1863(2):585–597.
  62. Stepan V, Sugano K, Yamada T, Park J, Dickinson CJ. Gastrin biosynthesis in canine G cells.. Am J Physiol Gastrointest Liver Physiol 2002;282(5):G766–G775.
  63. Beltinger J, Hildebrand P, Drewe J, Christ A, Hlobil K, Ritz M. Effects of spiroglumide, a gastrin receptor antagonist, on acid secretion in humans.. Eur J Clin Invest 1999;29(2):153–159.
  64. Walsh JH, Richardson CT, Fordtran JS. pH dependence of acid secretion and gastrin release in normal and ulcer subjects.. J Clin Invest 1975;55(3):462–468.
  65. García‐Sancho M, Rodríguez‐Franco F, Sainz A, Rodríguez A, Silván G, Illera JC. Serum gastrin in canine chronic lymphocytic–plasmacytic enteritis.. Can Vet J 2005;46(7):630–634.
  66. Wolfe MM, Soll AH. The physiology of gastric acid secretion.. N Engl J Med 1988;319:1707–1715.
  67. Code CF. Reflections on histamine, gastric secretion and the H2 receptor.. N Engl J Med 1977;296:1459–1462.
  68. Hirschowitz BI. An update on histamine receptors and the gastrointestinal tract.. Dig Dis Sci 1985;30:998–1004.
  69. Shawaf T, El‐Deeb WM, Elgioushy M. The contribution of specific and nonspecific biomarkers in diagnosis of equine gastric ulcer syndrome (EGUS) under field condition.. J Equine Vet Sci 2020;84:102853.
  70. Mohamadkhani A, Darvish Moghaddam S, Salmanroghani H, Allafsghari A, Yazdanbod A, Mirzaei M. Are the serum biomarkers pepsinogen I and II good predictors for the detection of subjects with atrophic gastritis in areas that have different gastric cancer incidence?. Arch Iran Med 2013;16(4):208–212.
  71. Yusuf FS. Formulation and in‐vitro evaluation of floating microballoons of stavudine.. Univ J Pharm Res 2016;1:13–19.
  72. Zhang XM, Li JX, Zhang GY, Li XH, Gu H. The value of serum pepsinogen concentrations for the diagnosis of gastric diseases in Chinese Han people in midsouth China.. BMC Gastroenterol 2014;14:3.
  73. Ning P, Sun L, Liu H, Yuan Y. Expression of pepsinogen C in gastric cancer and precancerous diseases and its clinical significance.. Chin J Clin Oncol 2004;1:422–426.
  74. Miki K. Gastric cancer screening using the serum pepsinogen test method.. Gastric Cancer 2006;9:245–253.
  75. Boutemine IM, Amri M, Amir ZC, Fitting C, Mecherara‐Idjeri S, Layaida K. Gastro‐protective, therapeutic and anti‐inflammatory activities of Pistacia lentiscus L. fatty oil against ethanol‐induced gastric ulcers in rats.. J Ethnopharmacol 2018;224:273–282.
  76. Cai JP, Wu YJ, Li C, Feng MY, Shi QT, Li R. Panax ginseng polysaccharide suppresses metastasis via modulating twist expression in gastric cancer.. Int J Biol Macromol 2013;57:22–25.
  77. Foreman JH, Grubb TL, Inoue OJ, Banner SE, Ball KT. Efficacy of single‐dose intravenous phenylbutazone and flunixin meglumine before, during and after exercise in an experimental reversible model of foot lameness in horses.. Equine Vet J 2010;42(S38):601–605.
  78. Moorman VJ, Reiser RF 2nd, Peterson ML, McIlwraith CW, Kawcak CE. Effect of forelimb lameness on hoof kinematics of horses at a trot.. Am J Vet Res 2013;74(9):1183–1191.
  79. Foreman JH, Barange A, Lawrence LM, Hungerford LL. Effects of single‐dose intravenous phenylbutazone on experimentally induced, reversible lameness in the horse.. J Vet Pharmacol Ther 2008;31(1):39–44.
  80. Taguchi T, Morales Yniguez FJ, Takawira C, Andrews FM, Lopez MJ. Agmatine administration effects on equine gastric ulceration and lameness.. J Clin Med 2022;11(24):72–83.
  81. Foreman JH, Ruemmler R. Phenylbutazone and flunixin meglumine used singly or in combination in experimental lameness in horses.. Equine Vet J 2011;43(S40):12–17.
  82. Hu HH, MacAllister CG, Payton ME, Erkert RS. Evaluation of the analgesic effects of phenylbutazone administered at a high or low dosage in horses with chronic lameness.. J Am Vet Med Assoc 2005;226(3):414–417.
  83. Mercer MA, McKenzie HC, Byron CR, Pleasant RS, Bogers SH, Council‐Troche RM. Pharmacokinetics and clinical efficacy of acetaminophen (paracetamol) in adult horses with mechanically induced lameness.. Equine Vet J 2023;55(3):524–533.
  84. Grady SE, Lescun TB, Moore GE, Cooper BR, Davern AJ, Brunner TJ. Ketorolac is not more effective than flunixin meglumine or phenylbutazone in reducing foot pain in horses.. J Equine Vet Sci 2020;94:103204.
Subscribe to our newsletter
Join 99,021 horse owners like you who receive our email updates on horse health and nutrition.